Results 211 to 220 of about 75,980 (291)

Treatment landscape from first‐ to third‐line therapy and quality of life data of patients with pancreatic cancer from the prospective German PARAGON (Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer) registry (IKF‐PARAGON study)

International Journal of Cancer, EarlyView.
What's New? Pancreatic cancer often is diagnosed at advanced stages. As a result, treatment regimens frequently are aggressive, with substantial side effects that impact quality of life (QoL). This study examined the treatment landscape, from neoadjuvant therapy to palliative care, in the context of QoL among pancreatic cancer patients in Germany. Most
Thorsten O. Goetze, Salah‐Eddin Al‐Batran, Ruediger Liersch, Lars Scheuer, Thomas Goehler, Ulrich Kaiser, Claudio Denzlinger, Stephan Brandl, Daniel Pink, Jens Uhlig, Michael Maasberg, Maria Loose, Marina Schaaf, Disorn Sookthai, Bianca Zäpf, Claudia Pauligk, Timursah Habibzade, Ralf‐Dieter Hofheinz, Christine Koch, for the AIO Study Group   +19 more
wiley   +1 more source

Bayesian Estimation of Multicomponent Stress-Strength Model Using Progressively Censored Data from the Inverse Rayleigh Distribution. [PDF]

Entropy (Basel)
Yılmaz A.
europepmc   +1 more source

Characteristics and overall survival in patients with T1 melanoma: A nationwide matched cohort study

International Journal of Cancer, EarlyView.
What's New? Thin cutaneous malignant melanoma has an excellent ten‐year melanoma‐specific survival of 93%–97%. Moreover, the incidence of melanoma is higher among individuals with high socioeconomic status, which may protect them from other diseases. This nationwide matched cohort study found that patients with thin cutaneous malignant melanoma have a ...
Ylva Naeser, Rasmus Mikiver, Karolin Isaksson, Mats Lambe, Gustav J. Ullenhag   +4 more
wiley   +1 more source

Analysis of Weibull time metrics using normal operating via partially accelerated tests with improved adaptive progressive censoring and its applications. [PDF]

Sci Rep
Elshahhat A, Alotaibi R, Nassar M.
europepmc   +1 more source

Efficacy and safety of fruquintinib combined with albumin‐bound paclitaxel as second‐line therapy for advanced gastric cancer following failure of PD‐1 inhibitor‐containing treatment (TACTIC GC‐01): A phase II single‐arm study

International Journal of Cancer, EarlyView.
What's New? Anti‐angiogenic drugs have shown promising efficacy as a second‐line treatment for advanced gastric cancer. However, it remains unclear how alterations in the tumor microenvironment following first‐line immunotherapy may impact tumor angiogenesis and influence subsequent therapeutic outcomes. This single‐arm study prospectively explored the
Xiaoting Ma, Kai Ou, Xiu Liu, Biyang Cao, Wenwei Yang, Jingyu Lu, Letian Zhang, Qi Wang, Lizhen Gao, Zhichao Jiang, Yongkun Sun, Lin Yang   +11 more
wiley   +1 more source

A-calibration: assessment of prediction models for survival data under censoring. [PDF]

BMC Med Res Methodol
Simonsen MR, Waagepetersen RP.
europepmc   +1 more source

Pubertal timing and incident uterine cancer in the Sister Study cohort

International Journal of Cancer, EarlyView.
What's New? Younger age at menarche is an established risk factor for uterine cancer. Age at onset of breast development (thelarche), the earliest marker of pubertal estrogen exposure unopposed by progesterone, may also be relevant to uterine cancer risk, but this association has not been explored. Using data from the US prospective Sister Study cohort,
Ariayana N. Harrell, Katie M. O'Brien, Natalie D. Shaw, Dale P. Sandler, Mandy Goldberg   +4 more
wiley   +1 more source

Statistical learning methods for improving predictive performance in time-dependent survival models. [PDF]

Genomics Inform
Seo H, Chung W.
europepmc   +1 more source

Changes in 1‐year relative survival of patients with cancer during the COVID‐19 pandemic in Denmark, Finland, Iceland, Norway, and Sweden: A population‐based cohort study

International Journal of Cancer, EarlyView.
What's New? In the first year of the COVID‐19 pandemic, cancer reporting in the Nordic countries declined, presumably owing to delays in cancer diagnosis. How the pandemic impacted cancer survival in these countries, however, remains unclear. Using data from Nordic cancer registries that together include more than 27 million people, the authors of the ...
Fernando Gonzalez Yli‐Mäyry, Tomas Tanskanen, Karri Seppä, Anna L. V. Johansson, Charlotte Wessel Skovlund, Lina Steinrud Mørch, Søren Friis, Simon Mathis Kønig, Tom Børge Johannesen, Tor Åge Myklebust, Sasha Pejicic, David Pettersson, Eva María Guðmundsdóttir, Sirpa Heinävaara, Nea Malila, Joonas Miettinen, Johan Ahlgren, Giske Ursin, Janne Pitkäniemi   +18 more
wiley   +1 more source

Demystifying Clone-Censor-Weighting to Studying Treatment Initiation Windows: An Example Using Publicly Available Synthetic Medicare Claims Data. [PDF]

Pharmacoepidemiol Drug Saf
Webster-Clark M, Li Y, Dell'Aniello S, Platt RW.   +3 more
europepmc   +1 more source